(Reuters) - In a filing with the U.S. Securities and Exchange Commission, the biopharmaceutical company said it will continue to consider offers from interested parties.
Back in January Cell Therapeutics made an unsolicited offer where it would issue 29 million shares to DOR shareholders, representing 19.9 percent of its outstanding stock.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment